AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35722126 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity integrated into learning (daily PA unit of 45 min over 3 years)
Number of subjects: 3000
Study 35722126 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no specific intervention mentioned)
Number of subjects: 3000
Study 35722590 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 0
Study 35722590 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 0
Study 35722822 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-1001 (125-1400 mg orally, twice daily)
Number of subjects: 47
Study 35723247 — intervention group
Group type: EXPERIMENTAL
Intervention: None/mild LVOT calcium
Number of subjects: 107
Study 35723247 — intervention group
Group type: COMPARATOR
Intervention: Moderate/severe LVOT calcium
Number of subjects: 107
Study 35723668 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Person Intervention
Number of subjects: 0
Study 35723668 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Intervention
Number of subjects: 0
Study 35723668 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study 35723793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative breast MRI
Number of subjects: 957
Study 35723793 — intervention group
Group type: COMPARATOR
Intervention: No pre-operative breast MRI
Number of subjects: 957
Study 35723922 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnestic MCI
Number of subjects: 76
Study 35723922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonamnestic MCI
Number of subjects: 76
Study 35723922 — intervention group
Group type: COMPARATOR
Intervention: Controls with normal cognition
Number of subjects: 76
Study 35723961 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive taping applied over the seroma fluctuation area for 5 days
Number of subjects: 35
Study 35724253 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Based Participatory Research (CBPR)
Number of subjects: 0
Study 35724253 — intervention group
Group type: EXPERIMENTAL
Intervention: Human-Centered Design
Number of subjects: 0
Study 35724253 — intervention group
Group type: EXPERIMENTAL
Intervention: CBPR and Human-Centered Design
Number of subjects: 0
Study 35724307 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Sleeve Gastrectomy (VSG)
Number of subjects: 0
Study 35724307 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 0
Study 35724307 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Caloric Restriction
Number of subjects: 0
Study 35724307 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 35724470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Work (DW) intervention
Number of subjects: 0
Study 35724624 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled in clinical trial
Number of subjects: 9516
Study 35724624 — intervention group
Group type: COMPARATOR
Intervention: Not enrolled in clinical trial
Number of subjects: 9516
Study 35724693 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical diagnosis (OD) of polyps with a resect and discard strategy
Number of subjects: 525
Study 35724693 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical diagnosis (OD) of ≤5-mm adenoma
Number of subjects: 525
Study 35724693 — intervention group
Group type: EXPERIMENTAL
Intervention: OD-histology surveillance interval concordance for ≤5-mm OD
Number of subjects: 525
Study 35724695 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR with h-APC ablation
Number of subjects: 84
Study 35724798 — intervention group
Group type: EXPERIMENTAL
Intervention: Befotertinib 50 mg (cohort A)
Number of subjects: 466
Study 35724798 — intervention group
Group type: EXPERIMENTAL
Intervention: Befotertinib 75 to 100 mg (cohort B)
Number of subjects: 466
Study 35725143 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss before treatment
Number of subjects: 153
Study 35725143 — intervention group
Group type: COMPARATOR
Intervention: Weight stable before treatment
Number of subjects: 153
Study 35725143 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain before treatment
Number of subjects: 153
Study 35725262 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization over 1 year
Number of subjects: 452
Study 35725262 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care consultations
Number of subjects: 452
Study 35725262 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging
Number of subjects: 452
Study 35725262 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol usage
Number of subjects: 452
Study 35725262 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization by risk profile
Number of subjects: 452
Study 35725407 — intervention group
Group type: EXPERIMENTAL
Intervention: EatsUp® mobile application
Number of subjects: 69
Study 35725542 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized prolonged discharge prescription forms plus education
Number of subjects: 20000
Study 35725542 — intervention group
Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 20000
Study 35725542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20000
Study 35725623 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with agalsidase alfa
Number of subjects: 4484
Study 35725670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosyntropin-stimulated 17-hydroxyprogesterone (17OHP)
Number of subjects: 65
Study 35725670 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum steroid profiling including 21-deoxycortisol and cosyntropin stimulation test with 17OHP
Number of subjects: 65
Study 35725670 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCAH diagnosis
Number of subjects: 65
Study 35725670 — intervention group
Group type: COMPARATOR
Intervention: Healthy patients in validation cohort
Number of subjects: 65
Study 35725741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sensorimotor map of forearm muscles using multiunit activity (MUA) and surface electromyography (EMG) during voluntary contractions of the extensor carpi radialis (ECR) and attempted motions in the flexor carpi radialis (FCR).
Number of subjects: 1
Study 35725741 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping and comparing left- and right-wrist-extensor-related activity throughout several sessions.
Number of subjects: 1
Study 35725741 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural signals at the within-electrode (multiunit) and cross-electrode (network) levels.
Number of subjects: 1
Study 35725741 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of somatotopy of active electrodes.
Number of subjects: 1
Study 35725917 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral iron supplementation (median cumulative intake 58.5 mg/kg at 28 days, 235.8 mg/kg through 36 weeks)
Number of subjects: 941
Study 35725917 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral iron supplementation (median cumulative intake 3.1 mg/kg at 28 days, 3.56 mg/kg through 36 weeks)
Number of subjects: 941
Study 35725917 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusions
Number of subjects: 941
Study 35725917 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 941
Study 35726133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 5711
Study 35726281 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback group
Number of subjects: 88
Study 35726281 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 88
Study 35726382 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal family psychosocial risk screening
Number of subjects: 19
Study 35726608 — intervention group
Group type: EXPERIMENTAL
Intervention: WDR62-related cognitive assessment
Number of subjects: 17
Study 35726608 — intervention group
Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Scales
Number of subjects: 17
Study 35726608 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up for progressive ataxia
Number of subjects: 17
Study 35726748 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition indices and alanine transaminase
Number of subjects: 2120
Study 35726748 — intervention group
Group type: EXPERIMENTAL
Intervention: Models including alanine transaminase alongside body composition measurements
Number of subjects: 2120
Study 35726748 — intervention group
Group type: EXPERIMENTAL
Intervention: Final models including five variables: body mass index-standard deviation score, android-to-gynoid-fat ratio, android-regional fat percent, trunk-regional fat percent and alanine transaminase
Number of subjects: 2120
Study 35726793 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ipilimumab/nivolumab followed by maintenance nivolumab
Number of subjects: 1
Study 35726793 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ipilimumab/nivolumab
Number of subjects: 1
Study 35726803 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Number of subjects: 0
Study 35726971 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated parenteral nutrition (PN)
Number of subjects: 134
Study 35726971 — intervention group
Group type: COMPARATOR
Intervention: Original parenteral nutrition (PN)
Number of subjects: 134
Study 35727117 — intervention group
Group type: EXPERIMENTAL
Intervention: Social networks intervention, details not available
Number of subjects: 0
Study 35727117 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 35727152 — intervention group
Group type: EXPERIMENTAL
Intervention: Knees with KOA
Number of subjects: 4634
Study 35727152 — intervention group
Group type: COMPARATOR
Intervention: Knees without KOA
Number of subjects: 4634
Study 35727196 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation (1 week post injury)
Number of subjects: 3179
Study 35727196 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 3179
Study 35727196 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation with a locking plate
Number of subjects: 3179
Study 35727196 — intervention group
Group type: COMPARATOR
Intervention: Reverse total shoulder arthroplasty (RTSA)
Number of subjects: 3179
Study 35727209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin to creatinine ratio
Number of subjects: 500
Study 35727209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction (EF)
Number of subjects: 500
Study 35727209 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast amount used
Number of subjects: 500
Study 35727324 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative information provided in consultations (average 11,086 words spoken, with a focus on 422 quantitative words).
Number of subjects: 112
Study 35727334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led coordinated pathway of care (NLC-RAPN)
Number of subjects: 151
Study 35727334 — intervention group
Group type: COMPARATOR
Intervention: Open partial nephrectomy (OPN)
Number of subjects: 151
Study 35727334 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted partial nephrectomy (RAPN)
Number of subjects: 151
Study 35727343 — intervention group
Group type: EXPERIMENTAL
Intervention: E-scooter accidents during working hours
Number of subjects: 170
Study 35727343 — intervention group
Group type: EXPERIMENTAL
Intervention: E-scooter accidents during off-working hours
Number of subjects: 170
Study 35727343 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 170
Study 35727476 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19
Number of subjects: 0
Study 35727476 — intervention group
Group type: COMPARATOR
Intervention: BLIN
Number of subjects: 0
Study 35727476 — intervention group
Group type: COMPARATOR
Intervention: INO
Number of subjects: 0
Study 35727476 — intervention group
Group type: COMPARATOR
Intervention: CHEMO
Number of subjects: 0
Study 35727609 — intervention group
Group type: EXPERIMENTAL
Intervention: TaiChi4Joint intervention (12-week remotely delivered tai chi classes via Zoom, 3 times a week)
Number of subjects: 39
Study 35727618 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth patch device with AI arrhythmia analysis for AF detection
Number of subjects: 178
Study 35727622 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally delivered treatment program for LBP (3 months duration)
Number of subjects: 2593
Study 35727629 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant bintrafusp alfa
Number of subjects: 14
Study 35727633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes (TILs) infusion after concurrent chemoradiotherapy (CCRT) plus i.m. IL-2 injections
Number of subjects: 27
Study 35727633 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 27
Study 35727758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessment according to WHO 2006 child-growth standards; ECD status using the Child Development Evaluation Test, 2nd Edition.
Number of subjects: 1176
Study 35727802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 477234
Study 35727876 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Noncompaction (LVNC) defined as NC:C ≥2 in at least one segment
Number of subjects: 25590
Study 35727876 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Noncompaction (LVNC)
Number of subjects: 25590
Study 35727876 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (1:10 on sex, gestational age, and weight)
Number of subjects: 25590
Study 35727884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 35727884 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 35728046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (SG)
Number of subjects: 0
Study 35728342 — intervention group
Group type: EXPERIMENTAL
Intervention: de novo metastatic breast cancer (dnMBC)
Number of subjects: 355
Study 35728342 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups (younger than 50, 50-69, 70 years or older)
Number of subjects: 355
Study 35728342 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-positive status
Number of subjects: 355
Study 35728342 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-negative, luminal A-like, and luminal B-like breast cancer subtypes
Number of subjects: 355
Study 35728621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 44
Study 35728746 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics (including omalizumab, benralizumab, mepolizumab, dupilumab, reslizumab)
Number of subjects: 2793
Study 35728746 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics (switching biologics)
Number of subjects: 2793
Study 35728746 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-anti-immunoglobulin E biologics
Number of subjects: 2793
Study 35728910 — intervention group
Group type: EXPERIMENTAL
Intervention: Causative bacterial infection
Number of subjects: 188
Study 35728910 — intervention group
Group type: EXPERIMENTAL
Intervention: Causative viral infection
Number of subjects: 188
Study 35728910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed bacterial and viral infections
Number of subjects: 188
Study 35728910 — intervention group
Group type: EXPERIMENTAL
Intervention: Unclassified infections
Number of subjects: 188
Study 35728925 — intervention group
Group type: EXPERIMENTAL
Intervention: Online estimator for predicting bronchopulmonary dysplasia (BPD) severity or death using demographic and clinical data.
Number of subjects: 9181
Study 35729005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab (500 mg IV every 3 weeks for Cycles 1-4, then 1000 mg Q6W) until disease progression or unacceptable toxicity
Number of subjects: 67
Study 35729005 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Number of subjects: 67
Study 35729357 — intervention group
Group type: COMPARATOR
Intervention: Eye-tracking-based test using SRLab-Tobii TX300 Eye tracker®
Number of subjects: 68
Study 35729365 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 13
Study 35729429 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment strategies, invasive procedures, revascularisation therapies, and use of mechanical circulatory support devices, including extracorporeal cardiopulmonary resuscitation.
Number of subjects: 400
Study 35729589 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE intervention delivered by non-specialist facilitators
Number of subjects: 59
Study 35729589 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE intervention
Number of subjects: 59
Study 35729620 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic drainage (AD)
Number of subjects: 30
Study 35729673 — intervention group
Group type: EXPERIMENTAL
Intervention: D-allulose (8.5 g consumed before iftar meal)
Number of subjects: 12
Study 35729736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training
Number of subjects: 80
Study 35729900 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies such as talking with family and friends, participating in family activities, physical activity, sleeping well at night, eating healthier, and increasing personal care.
Number of subjects: 3356
Study 35729900 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased time with screens, eating fast food, substance use, and frequent communication with health professionals.
Number of subjects: 3356
Study 35729900 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger women, primiparous women, and those with more exposure to COVID-19.
Number of subjects: 3356
Study 35729900 — intervention group
Group type: COMPARATOR
Intervention: General population of pregnant and postpartum women.
Number of subjects: 3356
Study 35730131 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05251749 (0.3-100 μM)
Number of subjects: 0
Study 35730213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 1131
Study 35730447 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic patients
Number of subjects: 740
Study 35730475 — intervention group
Group type: EXPERIMENTAL
Intervention: High tibial osteotomy (HTO)
Number of subjects: 16
Study 35730475 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched asymptomatic volunteers)
Number of subjects: 16
Study 35730586 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab + cyclophosphamide/bortezomib/dexamethasone (DARA + CyBorD)
Number of subjects: 87
Study 35730761 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail running races (40 to 171 km)
Number of subjects: 52
Study 35731242 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance following an FDG-negative nodule
Number of subjects: 126
Study 35731242 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic surgery for benign histopathology
Number of subjects: 126
Study 35731242 — intervention group
Group type: COMPARATOR
Intervention: Patients with malignant histopathology
Number of subjects: 126
Study 35731340 — intervention group
Group type: COMPARATOR
Intervention: US representative sample of men (no prostate cancer)
Number of subjects: 876
Study 35731373 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cold-water immersion (TCWI)
Number of subjects: 60
Study 35731373 — intervention group
Group type: COMPARATOR
Intervention: Ice massage (IM)
Number of subjects: 60
Study 35731464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention targeting addictive overeating with a displacement mechanism component
Number of subjects: 37
Study 35731464 — intervention group
Group type: EXPERIMENTAL
Intervention: Core 'Dread List' feature of the mobile intervention
Number of subjects: 37
Study 35731464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dread items related to school
Number of subjects: 37
Study 35731551 — intervention group
Group type: EXPERIMENTAL
Intervention: Uneven treadmill training (up to 12 sessions over 6 weeks)
Number of subjects: 3
Study 35731551 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation care
Number of subjects: 3
Study 35731565 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth lifestyle intervention
Number of subjects: 68
Study 35731565 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 68
Study 35731564 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification
Number of subjects: 434
Study 35731564 — intervention group
Group type: EXPERIMENTAL
Intervention: Neumorphism
Number of subjects: 434
Study 35731564 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 434
Study 35731566 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care management activities during patient encounters
Number of subjects: 176
Study 35731566 — intervention group
Group type: COMPARATOR
Intervention: Comparison of morbidity and management patterns between private and public sectors
Number of subjects: 176
Study 35731634 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based integrated HIV and sexual and reproductive health intervention (CHIEDZA) during the COVID-19 pandemic
Number of subjects: 0
Study 35731948 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin AUC0-24/MIC target of 58
Number of subjects: 290
Study 35731948 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin AUC0-24/MIC of 118.3
Number of subjects: 290
Study 35731948 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine AUC0-24/MIC of 50.5
Number of subjects: 290
Study 35731948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide AUC0-24 of 379 mg × h/L
Number of subjects: 290
Study 35731991 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine, Lomustine, and Vincristine chemotherapy
Number of subjects: 0
Study 35732012 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-set response format in speech-weighted noise
Number of subjects: 250
Study 35732012 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-set response format
Number of subjects: 250
Study 35732012 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonetically similar words in speech-weighted noise
Number of subjects: 250